-
Head and Neck Mucosal Melanoma: Where Are We Now? Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-21
Abstract Purpose of Review To highlight recent and relevant treatment considerations while managing mucosal melanoma. Recent Findings Evidence is building to support the use of targeted therapy and immunotherapy while managing mucosal melanoma. Summary Surgical resection with postoperative radiotherapy plays a major role in managing resectable disease. Recent studies evaluate the addition of targeted
-
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML) Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-19 Michael Wysota, Marina Konopleva, Shane Mitchell
-
Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-19 Susell Parra-Rojas, Rocío Trinidad Velázquez-Cayón, Acorán Borges-Gil, Juan Luis Mejías-Torrus, Juliana Cassol-Spanemberg
Purpose of Review It is recognized that patients undergoing cancer treatment experience different adverse effects depending on the type of therapy they received. The objective of this work is to provide a scientific evidence-based protocol for oral care in cancer patients. Cancer resection surgery, chemotherapy, and radiotherapy can cause important complications that impact patients’ quality of life
-
Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-15 Allison R. Valerius, Mason J. Webb, Nouran Hammad, Ugur Sener, Rachna Malani
-
Metronomic Chemotherapy in Elderly Patients Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-07 Arianna Bandini, Pasquale Fabio Calabrò, Marta Banchi, Paola Orlandi, Guido Bocci
-
Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-03-02 Bartosz Małkiewicz, Gabriela Świrkosz, Wojciech Lewandowski, Katarzyna Demska, Zuzanna Szczepaniak, Jakub Karwacki, Wojciech Krajewski, Tomasz Szydełko
-
An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-24 Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valerio Bonavolontà, Cristina Cenci, Stefano Magno, Vittoria Barberi, Antimo Moretti, Zein Mersini Besharat, Giovanni Iolascon, Carlo Baldari, Elisabetta Ferretti, Andrea Botticelli, Ida Paris, Giovanni Scambia, Silvia Migliaccio
-
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next? Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-23 Ilana Schlam, Joshua Dower, Filipa Lynce
-
Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-21 Chulkue Pak, Shinkyo Yoon, Jae Lyun Lee, Tak Yun, Inkeun Park
-
Oral Health in Patients with History of Head and Neck Cancer: Complexity and Benefits of a Targeted Oral Healthcare Pathway Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-20 Marion Florimond, Lucas T. Duong, Elodie Lours, Jean-Jacques Brau, François C. Ferré, Isabelle Fouilloux, Tchilalo Boukpessi
-
Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-20 Daniel Sentana-Lledo, Alicia K. Morgans
Purpose of Review Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in men with prostate cancer. This review summarizes the existing and emerging literature examining the cardiometabolic effects of androgen deprivation therapy (ADT) in prostate cancer. Recent Findings The evidence behind the metabolic effects of ADT is derived from older studies and has not been validated in
-
Current Trends and Challenges of Microbiome Research in Bladder Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-20
Abstract Purpose of the Review Microbiome research has provided valuable insights into the associations between microbial communities and bladder cancer. However, this field faces significant challenges that hinder the interpretation, generalization, and translation of findings into clinical practice. This review aims to elucidate these challenges and highlight the importance of addressing them for
-
Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-20 Cosima C. Hoch, Leonard Knoedler, Samuel Knoedler, Ali Bashiri Dezfouli, Benedikt Schmidl, Anskar Trill, Jennifer E. Douglas, Nithin D. Adappa, Fabian Stögbauer, Barbara Wollenberg
-
Establishing an Integrative Oncology Service: Essential Aspects of Program Development Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-15 Judith Lacey, Alissa Huston, Gabriel Lopez, Julia Ruiz Vozmediano, Chun Sing Lam, Santhosshi Narayanan, Weidong Lu, Ursula Wolf, Ishwaria M. Subbiah, Patrick Richard, Ana Maria Lopez, Santosh Rao, Moshe Frenkel
-
BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-10
Abstract Purpose of Review The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation. Recent Findings There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission
-
Blood–Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-08 Piiamaria S. Virtanen, Kyle J. Ortiz, Ajay Patel, William A. Blocher, Angela M. Richardson
-
Geographical Disparities in Lung Cancer in Canada: A Review Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-02-06
Abstract Purpose of Review The eastern provinces of Canada exhibit a heightened prevalence and mortality rate of lung cancer compared to their western counterparts. While established risk factors for lung cancer exist in Canada, there remains ambiguity regarding the underlying provincial and territorial trends. This review aims to identify and analyze potential contributors to healthcare inequality
-
Pelvic Floor Therapy and Initial Interventions for Pelvic Floor Dysfunction in Gynecologic Malignancies Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-31
Abstract Purpose of Review This review provides evidence-based updates for the first-line management approaches for pelvic floor disorders in patients with gynecologic malignancies, as well as important provider considerations when referring for pelvic floor physical therapy. Recent Findings Currently, there is strong evidence to recommend pelvic floor muscle training as initial treatment for urinary
-
The Dairy and Cancer Controversy: Milking the Evidence Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-30 Taylor E. Scialo, Crystal M. Pace, Donald I. Abrams
-
Elderly Rectal Cancer: An Updated Review Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-25
Abstract Purpose of Review Treatment of rectal cancer patients of advanced age should be modulated by life expectancy and tolerance. Due to the rapid advance of this field, we aim to conduct an updated review of this topic. Recent Findings The field of elderly rectal cancer has advanced a lot. This review covers all the treatment aspects of elderly rectal cancer, including the prognostic factor, surgery
-
Sarcopenia and Neuroendocrine Neoplasms Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-25 Dominique Clement, Sarah Brown, Monique V. Leerdam, Margot Tesselaar, John Ramage, Rajaventhan Srirajaskanthan
-
Germline Mutations and Ancestry in Prostate Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-24 Eudoxie Bataba, Kevin Babcock, Kathryn A. Isensee, Binil Eldhose, Indu Kohaar, Gregory T. Chesnut, Albert Dobi
-
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-09
Abstract Purpose of Review The goal of this review was to examine the role and practical applications of integrative oncology strategies in supporting immune checkpoint inhibitor (ICI) treatment of adult solid tumours. Recent Findings Beyond tumour-intrinsic factors, several patient-associated factors affect ICI response, including germline genetics, systemic inflammation, the gut microbiota, and diet
-
Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-05 Catherine Powers-James, Meroë Morse, Santhosshi Narayanan, Lois Ramondetta, Gabriel Lopez, Richard Wagner, Lorenzo Cohen
Purpose of Review After a cancer diagnosis, patients ask what they can do in addition to the recommended treatments to increase their survival. Many turn to integrative medicine modalities and lifestyle changes to improve their chances of survival. Numerous studies have demonstrated that lifestyle changes can significantly improve survival rates for cancer patients. Less support exists for the use
-
Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One? Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02
Abstract Purposeof Review This review examines the challenges of treating gastrointestinal cancer in the aging population, focusing on the importance of frailty assessment. Emphasized are the rise in gastrointestinal cancer incidence in older adults, advances in frailty assessments for patients with gastrointestinal cancer, the development of novel frailty markers, and a summary of recent trials. Recent
-
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Lily Carter, Vedika Apte, Arushi Shukla, Aruni Ghose, Raj Mamidi, Alexandra Petohazi, Shania Makker, Soirindhri Banerjee, Stergios Boussios, Giuseppe L. Banna
Purpose of Review The treatment of stage III N2 non-small cell lung cancer (NSCLC) remains debated. There is an absence of a universally agreed definition of resectability for this heterogeneous group and a lack of trial data. Recent Findings We reviewed and compared current international guidelines and evidence surrounding management of stage III N2 NSCLC. The Irish and Australian guidelines advise
-
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-04 Janina Stumpf, Othman Al-Sawaf
-
Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Mandy Jongbloed, Atulya A. Khosla, Valentina Bartolomeo, Karan Jatwani, Rohit Singh, Dirk K.M. De Ruysscher, Lizza E.L. Hendriks, Aakash Desai
-
Appendiceal Neuroendocrine Neoplasms: an Update for 2023 Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Pernille Holmager, Seppo W. Langer, Andreas Kjaer, Lene Ringholm, Rajendra Singh Garbyal, Carsten Palnæs Hansen, Mikkel Andreassen, Ulrich Knigge
-
Ovarian Suppression: Early Menopause, Late Effects Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Chaya Goldberg, Megan R. Greenberg, Alexandra Noveihed, Laila Agrawal, Coral Omene, Deborah Toppmeyer, Mridula A. George
-
PARP Inhibitors in Breast Cancer: a Short Communication Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Gordon R. Daly, Maen Monketh AlRawashdeh, Jason McGrath, Gavin P. Dowling, Luke Cox, Sindhuja Naidoo, Damir Vareslija, Arnold D. K Hill, Leonie Young
-
Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Prarthna V Bhardwaj, Shilpi Gupta, Alexa Elyash, Eleonora Teplinsky
-
Prolymphocytic Leukaemia: an Update on Biology and Treatment Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Dima El-Sharkawi, Claire Dearden
Purpose of Review This review summarises the recent advances in knowledge regarding the biology and treatment of prolymphocytic leukaemias. Recent Findings Both B-PLL and T-PLL are genetically complex, and the molecular landscape of these diseases has been well characterised recently. Diagnostic criteria for T-PLL have been refined with the publication of the first international consensus criteria
-
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Curr. Oncol. Rep. (IF 4.7) Pub Date : 2024-01-02 Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa Lynce, Sara M. Tolaney, Ilana Schlam
-
Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-12-22 Arthur Streit, Savvas Lampridis, Joseph Seitlinger, Stéphane Renaud, Tom Routledge, Andrea Bille
-
Racial Disparities in Breast Cancer: from Detection to Treatment Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-12-15
Abstract Purpose of Review Update on current racial disparities in the detection and treatment of breast cancer. Recent Findings Breast cancer remains the leading cause of cancer death among Black and Hispanic women. Mammography rates among Black and Hispanic women have surpassed those among White women, with studies now advocating for earlier initiation of breast cancer screening in Black women. Black
-
Surgery for Recurrent Epithelial Ovarian Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-12-13 Christina Fotopoulou, Ane Gerda Eriksson, Itai Yagel, Suk-Joon Chang, Myong Cheol Lim
-
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-12-13 Azka Ali, Stephanie L. Graff
-
Integrative Approaches in the Treatment of Patients Affected by Lymphoma Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-12-07 Ilana Levy Yurkovski, Francesca Andreazzoli, Eran Ben-Arye, Samuel Attias, Tamar Tadmor
-
Shifting Strategies in the Treatment of Pediatric Craniopharyngioma Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-28 Segev Gabay, Thomas E. Merchant, Frederick A. Boop, Jonathan Roth, Shlomi Constantini
-
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-28 Alistair Nash, Jenette Creaney
-
Limb Amputations in Cancer: Modern Perspectives, Outcomes, and Alternatives Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-24 Thien Huong N. Huynh, Davis R. Kuruvilla, Matthew D. Nester, Guston Zervoudakis, G. Douglas Letson, David M. Joyce, Odion T. Binitie, Alexander L. Lazarides
-
Immune Priming with Spatially Fractionated Radiation Therapy Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-18 Lauren Lukas, Hualin Zhang, Karen Cheng, Alan Epstein
-
Postmastectomy Functional Impairments Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-13 Eden Marco, Gabrielle Trépanier, Eugene Chang, Emma Mauti, Jennifer M. Jones, Toni Zhong
-
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-08 Niraj Neupane, Sangharsha Thapa, Abhinav Bhattarai, Kriti Ahuja, Ilana Schlam, Abhenil Mittal, Sara M. Tolaney, Paolo Tarantino
-
Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-04 Sushant Puri, Amina Chaudhry, Asnakech Bayable, Ashwin Ganesh, Ahmad Daher, Vijayakrishna K. Gadi, Stefania Maraka
-
Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-11-01 Celeste Manfredi, Francesco Ditonno, Antonio Franco, Eugenio Bologna, Leslie Claire Licari, Davide Arcaniolo, Andrea Tubaro, Cosimo De Nunzio, Alessandro Antonelli, Marco De Sio, Edward E. Cherullo, Riccardo Autorino
-
Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-31 Rebecca Brown
Abstract Neurofibromatosis type I (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis represent a diverse group of genetic tumor predisposition syndromes with a shared feature of tumors affecting the peripheral nerve sheaths. Purpose of Review Many advancements have been made in understanding the biologic underpinnings of these conditions, and in 2016 the first drug was approved by the FDA to
-
What Is New in Cutaneous T Cell Lymphoma? Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-24 Sarah Morgenroth, Andrea Roggo, Laura Pawlik, Reinhard Dummer, Egle Ramelyte
-
Novel Therapeutic Options for Small Cell Lung Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-23 Stefania Canova, Benedetta Trevisan, Maria Ida Abbate, Francesca Colonese, Luca Sala, Alice Baggi, Sofia Paola Bianchi, Anna D’Agostino, Diego Luigi Cortinovis
-
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-23 Elena Giudice, Mansoor Raza Mirza, Domenica Lorusso
-
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-20 Daria Arbuznikova, Matthias Eder, Anca-Ligia Grosu, Philipp T. Meyer, Christian Gratzke, Constantinos Zamboglou, Ann-Christin Eder
-
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-20 Anath C. Lionel, Jason Westin
Purpose of Review We review the recent practice-changing trials of anti-CD19 chimeric antigen receptor (CAR) T cell therapies in large B cell lymphoma (LBCL) including phase 3 comparisons with second-line standard-of-care (SOC) and phase 2 investigations in transplant-ineligible patients or as part of first-line treatment. Recent Findings ZUMA-7 found significantly improved overall survival and event-free
-
Advances in Treatment of Waldenström Macroglobulinemia Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-19 Eric Durot, Cécile Tomowiak
-
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-19 Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, Luca Isella, Marco Stellato, Michela Roberto, Roberto Iacovelli
-
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-06 Andrzej Dłubak, Jakub Karwacki, Katarzyna Logoń, Paulina Tomecka, Kinga Brawańska, Wojciech Krajewski, Tomasz Szydełko, Bartosz Małkiewicz
-
Incorporation of Palliative Care in Gynecologic Oncology Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-04 Christianne Persenaire, Daniel L. Spinosa, Lindsay W. Brubaker, Carolyn J. Lefkowits
-
Immune-Related Adverse Events in Patients with Lung Cancer Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-02 Guilherme Sacchi de Camargo Correia, Tanmayi Pai, Shenduo Li, Dana Connor, Yujie Zhao, Yanyan Lou, Rami Manochakian
-
Correction: Enhanced Recovery in Gynecologic Oncology Surgery-State of the Science. Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-01 Gregg Nelson
-
Correction to: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity. Curr. Oncol. Rep. (IF 4.7) Pub Date : 2023-10-01 Jesús Chamorro Pérez,Alfonso Cortes Salgado,Belén Perez-Mies,Jose Antonio Domínguez Rullán,Odile Ajuria-Illarramendi,Eva María Guerra Alia,Juan José Serrano Domingo